# Chronic Rhinosinusitis With Nasal Polyps FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/chronic-rhinosinusitis-with-nasal-polyps

> 8 upcoming FDA catalysts in chronic Rhinosinusitis With Nasal Polyps: TEZSPIRE® (tezepelumab, AZN) on Jan to Apr 2027 (topline data readout); TEZSPIRE® (tezepelumab, AZN) on January 2027 (primary completion); itepekimab (sar440340, SNY) on Feb to May 2027 (topline data readout); itepekimab (sar440340, SNY) on February 2027 (primary completion); and 4 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 7, 2025 | [Verekitug (upb-101) primary completion](https://sec-api.dev/pdufa/verekitug-upb-101) | UPB | Chronic Rhinosinusitis With Nasal Polyps | completed | "NCT06164704 (A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-07 (ACTUAL); Lead Sponsor Upstream Bio Inc.; Results First Posted 2026-09-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06164704)) |
| October 19, 2025 | [AMGEN INC PDUFA date](https://sec-api.dev/companies/amgn/catalysts) | AMGN | chronic rhinosinusitis with nasal polyps | scheduled | "•FDA review of the WAYPOINT Phase 3 data in patients with chronic rhinosinusitis with nasal polyps is ongoing with a PDUFA date of October 19, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000054/amgn-20250630earningsrelea.htm)) |
| January 29, 2026 | [Lunsekimig primary completion](https://sec-api.dev/pdufa/lunsekimig) | SNY | Chronic Rhinosinusitis With Nasal Polyps | completed | "NCT06454240 (A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-29 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06454240)) |
| September 18, 2026 | [Verekitug (upb-101) topline data readout](https://sec-api.dev/pdufa/verekitug-upb-101) | UPB | Chronic Rhinosinusitis With Nasal Polyps | completed | "NCT06164704 (A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-07 (ACTUAL); Lead Sponsor Upstream Bio Inc.; Results First Posted 2026-09-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06164704?tab=results)) |
| September 23, 2026 | [Itepekimab (sar440340) primary completion](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Rhinosinusitis With Nasal Polyps | completed | "NCT06834347 (A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-23 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06834347)) |
| Sep to Dec 2026 | [Itepekimab (sar440340) topline data readout](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT06834347 (A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-23 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06834347)) |
| September 24, 2026 | [Itepekimab (sar440340) primary completion](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Rhinosinusitis With Nasal Polyps | completed | "NCT06834360 (A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-24 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06834360)) |
| Sep to Dec 2026 | [Itepekimab (sar440340) topline data readout](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT06834360 (A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-24 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06834360)) |
| Jan to Apr 2027 | [TEZSPIRE® (tezepelumab) topline data readout](https://sec-api.dev/pdufa/tezepelumab) | AZN | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT06706817 (A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06706817)) |
| January 2027 | [TEZSPIRE® (tezepelumab) primary completion](https://sec-api.dev/pdufa/tezepelumab) | AZN | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT06706817 (A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06706817)) |
| Feb to May 2027 | [Itepekimab (sar440340) topline data readout](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT07424144 (An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-17 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07424144)) |
| February 2027 | [Itepekimab (sar440340) primary completion](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT07424144 (An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-17 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07424144)) |
| March 2028 | [TEZSPIRE® (tezepelumab) primary completion](https://sec-api.dev/pdufa/tezepelumab) | AZN | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT07520162 (A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07520162)) |
| Mar to Jun 2028 | [TEZSPIRE® (tezepelumab) topline data readout](https://sec-api.dev/pdufa/tezepelumab) | AZN | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT07520162 (A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07520162)) |
| Feb to May 2029 | [Lunsekimig topline data readout](https://sec-api.dev/pdufa/lunsekimig) | SNY | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT06914908 (Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-02-22 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06914908)) |
| February 2029 | [Lunsekimig primary completion](https://sec-api.dev/pdufa/lunsekimig) | SNY | Chronic Rhinosinusitis With Nasal Polyps | scheduled | "NCT06914908 (Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-02-22 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06914908)) |

## Drugs

- [Verekitug (upb-101)](https://sec-api.dev/pdufa/verekitug-upb-101) (UPB)
- [Lunsekimig](https://sec-api.dev/pdufa/lunsekimig) (SNY)
- [Itepekimab (sar440340)](https://sec-api.dev/pdufa/itepekimab-sar440340) (SNY)
- [TEZSPIRE® (tezepelumab)](https://sec-api.dev/pdufa/tezepelumab) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/chronic-rhinosinusitis-with-nasal-polyps.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Chronic Rhinosinusitis With Nasal Polyps FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/chronic-rhinosinusitis-with-nasal-polyps

```bibtex
@misc{secapidev_indications_chronic_rhinosinusitis_with_nasal_polyps_20261116,
  title        = {Chronic Rhinosinusitis With Nasal Polyps FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/chronic-rhinosinusitis-with-nasal-polyps}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_chronic_rhinosinusitis_with_nasal_polyps_20261116","title":"Chronic Rhinosinusitis With Nasal Polyps FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/chronic-rhinosinusitis-with-nasal-polyps","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
